The world of cell, gene and RNA therapy, which at one time may have seemed like a thing of fiction, is not only reality, but a reality that is growing at speed. With nearly 3,500 therapies in preclinical and clinical development globally, and almost $480m in start-up financing in the first quarter of 2021 alone, it is seeing a sharp rise in development and attention. And with 77 therapies in Phase III clinical trials, the industry is also teetering on the potential of even more exciting regenerative medicines becoming available to patients.
Of course, it is well known that with great power comes great responsibility and with strong ethical considerations, high cost...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?